• Improbable Developments

  • 著者： Salem Oaks
  • ポッドキャスト

『Improbable Developments』のカバーアート

Improbable Developments

著者： Salem Oaks
無料で聴く

  • サマリー

  • Every medicine in your pharmacy has a human story behind it. Real people doing real work and living real lives. We all have romantic ideas about scientists working late into the evening or doctors dropping everything to answer a phone call about a patient. You can almost envision the moment when one of those researchers finally solves an intellectual puzzle and leaps into action. Their eyes go from an empty stare to an alert laser-like focus. They sit a bit taller and start to read frantically. I am sure you’ve seen those movies too. But is it real? Is that how it really happens? That’s what we intend to explore in “Improbable Developments.” Each month we will talk to someone who was or is in the trenches of biopharma R&D and let them tell their story. We’ll be talking about medicines you may know and some that never saw the light of day. We’ll talk to people involved at the bench in the earliest stages through to those who run the clinical trials and present the data to regulators around the world. We'll even be talking to patients who have joined the effort. The science of drug discovery and development creates a rich landscape for all sorts of stories to unfold. The technical challenges, the urgency to help patients, career aspirations, the fight for resources, and many other factors all work together to produce a complex and enthralling human drama. In our monthly discussions, we will look at this from many different angles. Through our discussions, we hope to give you a real appreciation for the types of people behind the medicines you take and the medical devices you may use. You’ll get to know each of them a little bit and start to understand what they have in common and how different and unique they really are. We at Salem Oaks love to bring you these stories of people who are involved in the science, process, and profession of finding and developing new medicines. In our Emerging Researchers Series, we are even talking to people just entering the field and we hope you are enjoying their fresh energy and new ideas. But we need to ask for your help in continuing to bring you this podcast. As creators, we are looking for patrons who want to help us cover our expenses to bring you this service. We have established an account on Patreon that you can use to become a member of Salem Oaks at the Acorn or Sapling levels. Members receive exclusive benefits that you can read about at www.patreon.com/salemoaks. Thank You for your support. We truly appreciate it.
    Copyright 2023 Salem Oaks
    続きを読む 一部表示
エピソード
  • Amy Grover: Building Bridges Between Patients and Biopharma

    Amy Grover: Building Bridges Between Patients and Biopharma
    2021/08/17
    “Pharmaceutical companies sometimes have a bad rap of being, you know, big, bad pharmacy. But I learned that the patient or the people I am working with right now are just as passionate and just as dedicated to the patient community as I am.” Amy Grover, Director of Patient Advocacy at Catalyst Pharmaceuticals

    Amy Grover is a familiar face to the rare disease community. She spent 10 years at Global Genes before joining Catalyst Pharmaceuticals. At Global Genes she learned about rare diseases and the challenges they create for people. In her job now, she is working to bridge the gap between biopharma and the patients and families affected diseases like Lambert-Eaton Myasthenic Syndrome (LEMS). Sounds like a familiar mission.

    Amy moved from the patient side to industry much like I moved from industry to the patient world. We both were surprised by a few things that we saw as we passed through the looking glass between the two. We both recognize that one of the first steps to bridging this gap is mutual respect. If we work on this, the benefits of partnering will flow.

    I really enjoyed sharing insights looking at the problem from both directions.

    www.catlystpharma.com

    続きを読む 一部表示
    36 分
  • Helping the Patients He Can. For Free. For Life. - Stanley Crooke, MD, PhD

    Helping the Patients He Can. For Free. For Life. - Stanley Crooke, MD, PhD
    2021/07/26

    Imagine you are one of only 10 people in the world with a disease.  People with ultra-rare conditions have little hope of attracting research funding to find treatments to work for them.  The investments just don’t make sense to for-profit businesses.

    Our guest, Dr. Stanley Crooke, MD, PHD is leading an effort to change this.  After an illustrious career in pharma and founding the RNA Therapy company Ionis Pharmaceuticals, he is blazing a new trail.  He has founded n-Lorem, a non-profit organization that works with families affected by these ultrarare conditions.  N-Lorem works to find, develop, and provide new RNA treatments for free, for life. 

    RNA therapy, which includes anti-sense oligonucleotides, has been a dream for researchers for decades.  Dr. Crooke has been at the forefront of this work.  Now that years of labor are starting to bear fruit, he is looking to a new chapter.  A way to give back.  The question has changed from, “Can We?” to, “How can we not?” 

    https://www.nlorem.org/     https://www.ionispharma.com/  

    続きを読む 一部表示
    35 分
  • Alison Bateman-House, MPH, PhD: Not can we… but should we? Bioethics

    Alison Bateman-House, MPH, PhD: Not can we… but should we? Bioethics
    2021/05/17
    “I don't think a bioethicist is normally who people have come to their elementary school career day. So, we are a novel breed to many people.” Alison Bateman-House, PhD

    That is how our latest guest on Improbable Developments reflected on her chosen profession, bioethics. It is a field where scientists do not ask the questions about whether they can run an experiment or clinical study, but whether they should. Until recently, most people would not even know the field existed let alone give a good example of where it made a difference. 

    But COVID has changed that. 

    • Who should be vaccinated first?
    • How do we ensure equity in distributing the vaccine?
    • If we run low on oxygen or ICU beds, who do we treat?
    • Should we expand access to experimental or repurposed drugs before they have been tested?

    These are ethical questions that require considering multiple dimensions and perspectives. They are difficult questions. They are very human questions. 

    Tune in to learn how Alison Bateman-House was led into this challenging field and the work she is doing today on policy, clinical trial design, and ethics consulting. Her career path is fascinating to say the least. 

    https://med.nyu.edu/faculty/alison-bateman-house

    https://www.youtube.com/watch?v=WM8bTdBs-cw To see how MTV inspired Alison to think about bioethics as a career.

    https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/research/working-group-compassionate-use-preapproval-access

    https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/research/working-group-pediatric-gene-therapy-medical-ethics
    続きを読む 一部表示
    44 分

あらすじ・解説

Every medicine in your pharmacy has a human story behind it. Real people doing real work and living real lives. We all have romantic ideas about scientists working late into the evening or doctors dropping everything to answer a phone call about a patient. You can almost envision the moment when one of those researchers finally solves an intellectual puzzle and leaps into action. Their eyes go from an empty stare to an alert laser-like focus. They sit a bit taller and start to read frantically. I am sure you’ve seen those movies too. But is it real? Is that how it really happens? That’s what we intend to explore in “Improbable Developments.” Each month we will talk to someone who was or is in the trenches of biopharma R&D and let them tell their story. We’ll be talking about medicines you may know and some that never saw the light of day. We’ll talk to people involved at the bench in the earliest stages through to those who run the clinical trials and present the data to regulators around the world. We'll even be talking to patients who have joined the effort. The science of drug discovery and development creates a rich landscape for all sorts of stories to unfold. The technical challenges, the urgency to help patients, career aspirations, the fight for resources, and many other factors all work together to produce a complex and enthralling human drama. In our monthly discussions, we will look at this from many different angles. Through our discussions, we hope to give you a real appreciation for the types of people behind the medicines you take and the medical devices you may use. You’ll get to know each of them a little bit and start to understand what they have in common and how different and unique they really are. We at Salem Oaks love to bring you these stories of people who are involved in the science, process, and profession of finding and developing new medicines. In our Emerging Researchers Series, we are even talking to people just entering the field and we hope you are enjoying their fresh energy and new ideas. But we need to ask for your help in continuing to bring you this podcast. As creators, we are looking for patrons who want to help us cover our expenses to bring you this service. We have established an account on Patreon that you can use to become a member of Salem Oaks at the Acorn or Sapling levels. Members receive exclusive benefits that you can read about at www.patreon.com/salemoaks. Thank You for your support. We truly appreciate it.
Copyright 2023 Salem Oaks
身体的病い・疾患 衛生・健康的な生活 生物科学 化学
続きを読む 一部表示

Improbable Developmentsに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。